Clinical Trials Logo

Filter by:
NCT ID: NCT03366818 Completed - Clinical trials for Acute Ischemic Stroke

New Stent Retriever, VERSI System for AIS

Start date: September 21, 2017
Phase: N/A
Study type: Interventional

To confirm efficacy and safety of VERSI system for acute ischemic stroke

NCT ID: NCT03366545 Recruiting - Heart Failure Clinical Trials

Observation of Clinical Routine Care for Heart Failure Patients Implanted With BIOTRONIK CRT Devices

BIO|STREAM HF
Start date: May 14, 2018
Phase:
Study type: Observational [Patient Registry]

The registry is primarily designed to assess outcome, efficacy and residual safety aspects of CRT based on long-term data from an unselected, real-life clinical set-up. Moreover, the observation of the patient status should help to find possible predictors for HF events and to identify areas of improvement for CRT and for CRT device settings.

NCT ID: NCT03366428 Completed - Clinical trials for Malignant Neoplasm of Breast

Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer

Start date: December 26, 2017
Phase: Phase 1
Study type: Interventional

This study will look at the effect on the QTc interval and pharmacokinetics after multiple dosing in subjects with HER2-expressing metastatic and/or unresectable breast cancer.

NCT ID: NCT03364751 Completed - Clinical trials for Periodontal Diseases

Effect of Switching From Cigarette Smoking to the Use of IQOS on Periodontitis Treatment Outcome

Start date: November 7, 2017
Phase: N/A
Study type: Interventional

The purpose of this study was to demonstrate in patients with generalized chronic periodontitis that switching from cigarette smoking to using IQOS improves the response to periodontal therapy and the overall oral health status compared to continuing cigarette smoking. Note: "IQOS" is the Tobacco Heating System (THS) with Marlboro Heatsticks, marketed in Japan under the brand name IQOS

NCT ID: NCT03364244 Completed - Clinical trials for Pulmonary Arterial Hypertension

Revatio Special Investigation for Long-term Use in Pediatric Patients

Start date: November 30, 2017
Phase:
Study type: Observational

Secondary data collection study: safety and effectiveness of Revatio in pediatric patients under Japanese medical practice

NCT ID: NCT03361956 Completed - Hepatitis B Clinical Trials

An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection

Start date: February 13, 2018
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to evaluate efficacy of 24 weeks of study treatment, in terms of changes in hepatitis B surface antigen (HBsAg) levels.

NCT ID: NCT03361865 Completed - Clinical trials for UC (Urothelial Cancer)

Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)

Start date: December 4, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the efficacy and safety of pembrolizumab + epacadostat vs pembrolizumab + placebo in participants with cisplatin-ineligible urothelial carcinoma.

NCT ID: NCT03361748 Completed - Multiple Myeloma Clinical Trials

Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma

KarMMa
Start date: December 18, 2017
Phase: Phase 2
Study type: Interventional

This is an open label, single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma. A leukapheresis procedure will be performed to manufacture bb2121 chimeric antigen receptor (CAR) modified T cells. Prior to bb2121 infusion subjects will receive lymphodepleting therapy with fludarabine and cyclophosphamide.

NCT ID: NCT03361540 Completed - Healthy Subjects Clinical Trials

ASP8302 Single and Multiple Ascending Oral Dose Study in Non-elderly Healthy Japanese Subjects

Start date: November 14, 2017
Phase: Phase 1
Study type: Interventional

The objective of this study is to evaluate the safety, tolerability and pharmacokinetic of single/multiple ascending oral doses of ASP8302 in non-elderly healthy Japanese male and female subjects.

NCT ID: NCT03358472 Active, not recruiting - Clinical trials for Head and Neck Cancer

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

Start date: December 1, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).